Travere Therapeutics (TVTX) Curent Deferred Tax Liability (2015)

Travere Therapeutics (TVTX) reported Curent Deferred Tax Liability of $15.9 million for Q3 2015, up 82.86% quarter-over-quarter from $8.7 million in Q2 2015.

Travere Therapeutics (TVTX) Curent Deferred Tax Liability (2015) Analysis & Trends

Travere Therapeutics has reported Curent Deferred Tax Liability for 1 years, with the latest figure at $15.9 million in Q3 2015.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Curent Deferred Tax (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Travere Therapeutics 5.07 Bn 4.99 Bn 102.38 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2015 15.89 Mn
Sep 30, 2015 15.89 Mn
Jun 30, 2015 8.69 Mn
Jun 30, 2015 8.69 Mn
Mar 31, 2015 8.69 Mn
Mar 31, 2015 8.69 Mn